(MENAFN- GlobeNewsWire - Nasdaq) Growth strategies focus on affordable D2C kits, retail expansion, NGS innovation, digital integration and privacy safeguards to capture personalized and preventive care demandDublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Genetic Testing Market Report by Tests, Products, Technology, Disease, End-Users, Countries and Company Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering.
The global genetic testing market is projected to grow from US$ 21.84 billion in 2025 to US$ 50.29 billion by 2034, registering a compound annual growth rate of 9.71% from 2026 to 2034. Market expansion is supported by rising demand for personalized medicine, advances in next-generation sequencing, broader access to direct-to-consumer testing, and increased awareness of preventive healthcare.
Genetic testing is gaining importance across predictive screening, oncology, pharmacogenomics, prenatal assessment, carrier testing, rare disease diagnosis, and wellness applications. Technologies including PCR, DNA sequencing, microarrays, DNA methylation analysis, and SNP-based profiling are improving accuracy, scalability, and clinical utility. Continued reductions in sequencing costs, combined with expanding laboratory capabilities and digital-health integration, are strengthening adoption among healthcare providers and consumers.
Key Genetic Testing Market Growth Drivers
Demand for comprehensive wellness and epigenetic testing is creating new commercial opportunities. In October 2024, EpiMedTech introduced epiGeneComplete, which evaluates aging markers, metabolic performance, inflammation, stress responses, and other biological indicators using next-generation sequencing, DNA methylation analysis, and SNP markers. Growing interest in longevity, fitness, and proactive health management is increasing demand for lifestyle-focused genomic services.
The direct-to-consumer segment is also expanding as at-home kits provide convenient access to ancestry, health predisposition, nutrition, and wellness insights. In November 2024, ProPhase Labs launched DNA Complete, Inc., a wholly owned subsidiary focused on accessible D2C DNA testing. Improved digital reporting, wider distribution, stronger privacy controls, and greater regulatory clarity are supporting consumer adoption.
Retail availability is further improving genetic testing accessibility. In November 2024, Myriad Genetics launched SneakPeek, an at-home gender test distributed through more than 8,800 U.S. retail stores. The growing presence of prenatal tests, ancestry kits, disease-risk screening products, and wellness assessments across pharmacies, supermarkets, and online marketplaces is bringing genetic testing into routine consumer healthcare.
Market Challenges
Data privacy and regulatory compliance remain significant concerns. Genetic information requires stringent safeguards against unauthorized access, third-party sharing, and discriminatory use. Compliance with GDPR, HIPAA, and country-specific genomic data regulations can increase operating costs, extend approval timelines, and complicate international expansion. Transparent data policies and secure infrastructure will be essential to maintaining consumer confidence.
High testing costs and unequal access also limit adoption, particularly in developing regions. Advanced equipment, specialized laboratory workflows, limited reimbursement, infrastructure gaps, and shortages of trained professionals restrict availability. Greater insurance coverage, lower operating costs, workforce development, and educational initiatives will be required to support broader global access.
Regional Genetic Testing Market Outlook
The United States remains a leading market due to its advanced healthcare infrastructure, substantial investment in precision medicine, and widespread acceptance of at-home testing. Genomic profiling is increasingly used in cancer diagnostics, carrier screening, and pharmacogenomics, while retail distribution and digital-health platforms are expanding consumer access.
Germany is experiencing steady growth in NGS-based diagnostics, oncology testing, rare disease detection, carrier screening, and pharmacogenomic evaluation. Strict regulatory standards support test reliability, while healthcare digitalization and expanding diagnostic laboratory capacity are accelerating clinical adoption.
China is positioned among the fastest-growing genetic testing markets, supported by government investment in precision medicine, rising healthcare expenditure, and an expanding domestic biotechnology industry. Prenatal testing, oncology genomics, carrier screening, and health-risk assessment represent major opportunities, although data-privacy requirements continue to influence commercial strategies.
Saudi Arabia is advancing genetic testing through healthcare modernization and precision medicine programs associated with Vision 2030. Demand is particularly strong for premarital, carrier, newborn, oncology, and rare disease screening. Government initiatives, private-sector investment, and partnerships with global diagnostic companies are strengthening local laboratory capabilities.
Recent Genetic Testing Industry Developments
In December 2025, Zydus Lifesciences collaborated with Myriad Genetics to introduce the MyRisk hereditary cancer test and related genomic assays across India. In October 2025, Gene Solutions partnered with AMPATH to establish a state-of-the-art genomics laboratory in Hyderabad and expand access to next-generation sequencing technologies. In September 2025, Mass General Brigham introduced a polygenic cardiovascular risk panel developed with Broad Clinical Labs to support earlier identification and management of inherited heart-related risks. In July 2025, Bupa launched its Medication Check DNA service. Results indicated that 99% of participants carried genetic variations capable of influencing responses to commonly prescribed medications.
Genetic Testing Market Segmentation
By Test: Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomic Testing, and Others. By Product: Consumables, Equipment, and Software & Services. By Technology: PCR, DNA Sequencing, Microarrays, and Others. By Disease: Cancer, Genetic Diseases, Cardiovascular Diseases, Rare Diseases, Infectious Diseases, and Others. By End-Users: Hospitals & Clinics, Diagnostic Laboratories, and Others.
Geographic Coverage: The report examines the United States and Canada in North America; France, Germany, Italy, Spain, the United Kingdom, Belgium, the Netherlands, and Turkey in Europe; China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, and New Zealand in Asia Pacific; Brazil, Mexico, and Argentina in Latin America; and Saudi Arabia, the UAE, and South Africa in the Middle East & Africa.
Competitive Landscape
The genetic testing market report evaluates major companies through corporate overviews, key personnel, recent developments, SWOT analysis, and revenue analysis. Companies covered include Abbott Laboratories, Danaher Corporation through Cepheid Inc., Illumina Inc., Bio-Rad Laboratories Inc., F Hoffmann-La Roche AG, DiaSorin, Revvity Inc., and Thermo Fisher Scientific Inc.
Ongoing innovation in sequencing, predictive analytics, consumer testing, and clinical genomics is expected to reshape the competitive landscape through 2034. Companies that combine validated testing platforms, secure data management, broad distribution, and actionable clinical insights will be well positioned to capture opportunities across diagnostic, predictive, and personalized healthcare applications.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment